Most online conversations reward certainty, and real life tends to be messier than that
Finally, clinicians should maintain a low threshold for evaluating patients who report unusual or severe gastrointestinal symptoms, as these may indicate inadvertent overdosing or other complications requiring intervention
Quiets food noise & reduces cravings*
Retatrutide is the first triple-agonist GLP-1/GIP/Glucagon medication in Phase 3 trials, made by Eli Lilly
Concerns about the potential association between certain diabetes medications and cardiovascular disease meant that in 2010 the FDA approved liraglutide on condition that Novo Nordisk conduct a post-marketing study to evaluate the drug's effect on the incidence of major cardiovascular events (Nielsen, DeChiaro, Goldman)
Insurance companies operate for a profit, so drug costs significantly impact coverage